Repository logo
 

Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate.

Published version
Peer-reviewed

Change log

Authors

Abstract

Regulatory B cells restrict immune and inflammatory responses across a number of contexts. This capacity is mediated primarily through the production of IL-10. Here we demonstrate that the induction of a regulatory program in human B cells is dependent on a metabolic priming event driven by cholesterol metabolism. Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate (GGPP) is required to specifically drive IL-10 production, and to attenuate Th1 responses. Furthermore, GGPP-dependent protein modifications control signaling through PI3Kδ-AKT-GSK3, which in turn promote BLIMP1-dependent IL-10 production. Inherited gene mutations in cholesterol metabolism result in a severe autoinflammatory syndrome termed mevalonate kinase deficiency (MKD). Consistent with our findings, B cells from MKD patients induce poor IL-10 responses and are functionally impaired. Moreover, metabolic supplementation with GGPP is able to reverse this defect. Collectively, our data define cholesterol metabolism as an integral metabolic pathway for the optimal functioning of human IL-10 producing regulatory B cells.

Description

Funder: Intramural Research Programs of the National Human Genome Research Institute

Keywords

Animals, Antigens, CD19, B-Lymphocytes, Regulatory, Cholesterol, Class I Phosphatidylinositol 3-Kinases, Coculture Techniques, Hereditary Autoinflammatory Diseases, Humans, Interleukin-10, Macrophages, Metabolic Syndrome, Mevalonate Kinase Deficiency, Mice, Phosphatidylinositol 3-Kinases, Polyisoprenyl Phosphates, Positive Regulatory Domain I-Binding Factor 1, Principal Component Analysis, Signal Transduction, Th1 Cells, Toll-Like Receptor 9, Tumor Necrosis Factor-alpha

Journal Title

Nat Commun

Conference Name

Journal ISSN

2041-1723
2041-1723

Volume Title

11

Publisher

Springer Science and Business Media LLC
Sponsorship
Wellcome Trust (206618/Z/17/Z)